The application for the renewal of the approval of the active substance emamectin was submitted on 26 November 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 9 September 2022 that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 24 November 2023 and 22 January 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in December 2026. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 30 months, until 15 May 2029.
Recital 43, Regulation (EU) 2026/2348
In force